LncRNA LIMp27 Regulates the DNA Damage Response through p27 in p53-Defective Cancer Cells

Adv Sci (Weinh). 2023 Mar;10(7):e2204599. doi: 10.1002/advs.202204599. Epub 2023 Jan 13.

Abstract

P53 inactivation occurs in about 50% of human cancers, where p53-driven p21 activity is devoid and p27 becomes essential for the establishment of the G1/S checkpoint upon DNA damage. Here, this work shows that the E2F1-responsive lncRNA LIMp27 selectively represses p27 expression and contributes to proliferation, tumorigenicity, and treatment resistance in p53-defective colon adenocarcinoma (COAD) cells. LIMp27 competes with p27 mRNA for binding to cytoplasmically localized hnRNA0, which otherwise stabilizes p27 mRNA leading to cell cycle arrest at the G0/G1 phase. In response to DNA damage, LIMp27 is upregulated in both wild-type and p53-mutant COAD cells, whereas cytoplasmic hnRNPA0 is only increased in p53-mutant COAD cells due to translocation from the nucleus. Moreover, high LIMp27 expression is associated with poor survival of p53-mutant but not wild-type p53 COAD patients. These results uncover an lncRNA mechanism that promotes p53-defective cancer pathogenesis and suggest that LIMp27 may constitute a target for the treatment of such cancers.

Keywords: E2F1; LIMp27; colon cancer; hnRNPA0; lncRNA; p27.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma*
  • Colonic Neoplasms*
  • Cyclin-Dependent Kinase Inhibitor p27* / metabolism
  • DNA Damage / genetics
  • Humans
  • RNA, Long Noncoding* / genetics
  • RNA, Messenger / genetics
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • RNA, Long Noncoding
  • RNA, Messenger
  • Tumor Suppressor Protein p53
  • CDKN1B protein, human
  • Cyclin-Dependent Kinase Inhibitor p27